Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887609 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2020.12.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
J Immunother Cancer
August 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Background: The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppressive agents. There is no data on the impact of resuming nivolumab on survival following recovery from the irAE and completion of immunosuppressive treatment.
View Article and Find Full Text PDFConcomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
J Cutan Pathol
June 2023
Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Article Synopsis
- A 73-year-old male with metastatic renal cell carcinoma developed both bullous pemphigoid (BP) and Grover disease (GD) while being treated with nivolumab, a type of immune checkpoint inhibitor (ICI).
- His skin condition included scaly papules and widespread lesions, with biopsies confirming both GD and BP through specific histopathological and immunofluorescence findings.
- The relationship between these ICI-induced conditions is complex, with T-cell activation potentially linking them, and the patient was effectively treated with dupilumab.
Nivolumab is a fully human immunoglobulin G4 immune checkpoint inhibitor antibody approved for use in the treatment of several malignancies such as lung cancer. Cutaneous reactions to checkpoint inhibitors are frequent, appearing in approximately 40% of patients. Although most of the reactions are well tolerated, these drugs can lead to severe cutaneous adverse reactions, but a quick recognition of the symptoms can significantly decrease their mortality.
View Article and Find Full Text PDFImmunotherapy-Resistant Vitreoretinal Metastatic Melanoma.
Ocul Oncol Pathol
March 2021
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Purpose: To describe 2 cases of vitreoretinal metastases in patients treated with immunotherapy for metastatic melanoma.
Methods: Retrospective case series.
Results: We pre-sent 2 patients with metastatic melanoma treated with systemic immunotherapy with subsequent development of ocular vitreoretinal metastasis.
Nivolumab-associated cutaneous T-cell lymphoma.
JAAD Case Rep
March 2021
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!